353 related articles for article (PubMed ID: 32664839)
1. The Current State of Potential Therapeutic Modalities for Glioblastoma Multiforme: A Clinical Review.
Mohtashami E; Shafaei-Bajestani N; Mollazadeh H; Mousavi SH; Jalili-Nik M; Sahebkar A; Afshari AR
Curr Drug Metab; 2020; 21(8):564-578. PubMed ID: 32664839
[TBL] [Abstract][Full Text] [Related]
2. The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme.
Bambury RM; Morris PG
Expert Rev Anticancer Ther; 2014 Aug; 14(8):955-64. PubMed ID: 24814143
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
Trials; 2018 May; 19(1):293. PubMed ID: 29801515
[TBL] [Abstract][Full Text] [Related]
4. Success and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions.
Corso CD; Bindra RS
Semin Radiat Oncol; 2016 Oct; 26(4):281-98. PubMed ID: 27619250
[TBL] [Abstract][Full Text] [Related]
5. Glioblastoma multiforme: a glance at advanced therapies based on nanotechnology.
Rezaei V; Rabiee A; Khademi F
J Chemother; 2020 May; 32(3):107-117. PubMed ID: 31984871
[TBL] [Abstract][Full Text] [Related]
6. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB
Front Immunol; 2020; 11():582106. PubMed ID: 33178210
[TBL] [Abstract][Full Text] [Related]
7. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
Shi F; Guo H; Zhang R; Liu H; Wu L; Wu Q; Liu J; Liu T; Zhang Q
Neuroscience; 2017 Mar; 346():298-308. PubMed ID: 28147244
[TBL] [Abstract][Full Text] [Related]
8. Recent Development in NKT-Based Immunotherapy of Glioblastoma: From Bench to Bedside.
Li Y; Sharma A; Maciaczyk J; Schmidt-Wolf IGH
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163235
[TBL] [Abstract][Full Text] [Related]
9. Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review.
Anjum K; Shagufta BI; Abbas SQ; Patel S; Khan I; Shah SAA; Akhter N; Hassan SSU
Biomed Pharmacother; 2017 Aug; 92():681-689. PubMed ID: 28582760
[TBL] [Abstract][Full Text] [Related]
10. Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.
Swartz AM; Li QJ; Sampson JH
Immunotherapy; 2014; 6(6):679-90. PubMed ID: 25186601
[TBL] [Abstract][Full Text] [Related]
11. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
12. Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme.
Okonogi N; Shirai K; Oike T; Murata K; Noda SE; Suzuki Y; Nakano T
Anticancer Res; 2015 Mar; 35(3):1229-35. PubMed ID: 25750269
[TBL] [Abstract][Full Text] [Related]
13. Advances in glioblastoma multiforme: Integrating therapy and pathology perspectives.
Shahcheraghi SH; Alimardani M; Lotfi M; Lotfi M; Uversky VN; Guetchueng ST; Palakurthi SS; Charbe NB; Hromić-Jahjefendić A; Aljabali AAA; Gadewar MM; Malik S; Goyal R; El-Tanani M; Mishra V; Mishra Y; Tambuwala MM
Pathol Res Pract; 2024 May; 257():155285. PubMed ID: 38653089
[TBL] [Abstract][Full Text] [Related]
14. Advances in immunotherapy for glioblastoma multiforme.
Mahmoud AB; Ajina R; Aref S; Darwish M; Alsayb M; Taher M; AlSharif SA; Hashem AM; Alkayyal AA
Front Immunol; 2022; 13():944452. PubMed ID: 36311781
[TBL] [Abstract][Full Text] [Related]
15. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
[TBL] [Abstract][Full Text] [Related]
16. Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme.
Ung N; Yang I
J Neurooncol; 2015 Jul; 123(3):473-81. PubMed ID: 26070553
[TBL] [Abstract][Full Text] [Related]
17. Advances in Immunotherapy for Glioblastoma Multiforme.
Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
[TBL] [Abstract][Full Text] [Related]
18. Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme.
Gainer JL; Sheehan JP; Larner JM; Jones DR
J Neurosurg; 2017 Feb; 126(2):460-466. PubMed ID: 27177177
[TBL] [Abstract][Full Text] [Related]
19. The Safety of available immunotherapy for the treatment of glioblastoma.
Farber SH; Elsamadicy AA; Atik AF; Suryadevara CM; Chongsathidkiet P; Fecci PE; Sampson JH
Expert Opin Drug Saf; 2017 Mar; 16(3):277-287. PubMed ID: 27989218
[TBL] [Abstract][Full Text] [Related]
20. Emerging treatment strategies for glioblastoma multiforme.
Carlsson SK; Brothers SP; Wahlestedt C
EMBO Mol Med; 2014 Nov; 6(11):1359-70. PubMed ID: 25312641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]